Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
new york top stories
14
×
san francisco top stories
14
×
boston blog main
boston top stories
new york blog main
san francisco blog main
san diego blog main
san diego top stories
biotech
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
indiana blog main
indiana top stories
texas blog main
drugs
merck
roche
akcea therapeutics
alnylam pharmaceuticals
boston
bristol-myers squibb
cancer
ceo
commissioner
drug development
What
medicine
14
×
drug
fda
approved
cancer
new
bio
patients
roundup
alnylam
big
ceo
disease
friday
genetic
goes
help
known
long
making
nobel
prize
study
therapy
time
treatment
week
aces
adapt
afternoon
ago
alnylam’s
alzheimer's
announced
approve
ask
atrophy
awaits
bad
biological
Language
unset
Current search:
medicine
×
" san francisco top stories "
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?